Comparison of Tigecycline and Vancomycin for Treatment of Experimental Foreign-body Infection Due to Methicillin-resistant Staphylococcus Aureus

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2009 Apr 15

PMID 19364855

Citations 5

Authors

Pierre Vaudaux

Benedicte Fleury

Asllan Gjinovci

Elzbieta Huggler

Manuela Tangomo-Bento

Daniel P Lew

Affiliations

Soon will be listed here.

Abstract

Twice-daily 7-day regimens of tigecycline (7 mg/kg) and vancomycin (50 mg/kg) were compared in a rat tissue cage model of chronic foreign-body infection due to methicillin (meticillin)-resistant Staphylococcus aureus strain MRGR3. Subcutaneously administered tigecycline reached levels in tissue cage fluid that were nearly equivalent or slightly superior to the antibiotic MIC (0.5 microg/ml) for strain MRGR3. After 7 days, equivalent, significant reductions in bacterial counts were recorded for tigecycline-treated and vancomycin-treated rats, compared with those for untreated animals.

Citing Articles

Molecular Basis of Non-β-Lactam Antibiotics Resistance in .

Lade H, Joo H, Kim J Antibiotics (Basel). 2022; 11(10).

PMID: 36290036 PMC: 9598170. DOI: 10.3390/antibiotics11101378.

Spontaneous Knee Hemarthrosis Due to Hypofibrinogenemia Following Tigecycline Treatment for Periprosthetic Joint Infection.

Balfousias T, Apostolopoulos A, Angelis S, Maris S, Papanikolaou A Cureus. 2019; 11(10):e5883.

PMID: 31772853 PMC: 6837269. DOI: 10.7759/cureus.5883.

Clinical Experience with Tigecycline in the Treatment of Prosthetic Joint Infections.

Lastinger A, McLeod N, Dietz M, Guilfoose J, Sarwari A J Bone Jt Infect. 2019; 4(3):126-132.

PMID: 31192112 PMC: 6536800. DOI: 10.7150/jbji.34866.

Effectiveness of a Glycylcycline Antibiotic for Reducing the Pathogenicity of Superantigen-Producing Methicillin-Resistant in Burn Wounds.

Nosanov L, Jo D, Randad P, Moffatt L, Carney B, Ortiz R Eplasty. 2017; 17:e27.

PMID: 28943993 PMC: 5600145.

Foreign Body Infection Models to Study Host-Pathogen Response and Antimicrobial Tolerance of Bacterial Biofilm.

Nowakowska J, Landmann R, Khanna N Antibiotics (Basel). 2016; 3(3):378-97.

PMID: 27025752 PMC: 4790362. DOI: 10.3390/antibiotics3030378.

References

Crandon J, Banevicius M, Nicolau D . Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother. 2008; 53(3):1165-9. PMC: 2650523. DOI: 10.1128/AAC.00647-08. View

Ong C, Babalola C, Nightingale C, Nicolau D . Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother. 2005; 56(3):498-501. DOI: 10.1093/jac/dki260. View

Lowy F . Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003; 111(9):1265-73. PMC: 154455. DOI: 10.1172/JCI18535. View

Chuard C, Herrmann M, Vaudaux P, Waldvogel F, Lew D . Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother. 1991; 35(12):2611-6. PMC: 245440. DOI: 10.1128/AAC.35.12.2611. View

Vaudaux P, Francois P, Bisognano C, Schrenzel J, Lew D . Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002; 46(5):1503-9. PMC: 127155. DOI: 10.1128/AAC.46.5.1503-1509.2002. View

Bradford P, Petersen P, Young M, Jones C, Tischler M, OConnell J . Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother. 2005; 49(9):3903-9. PMC: 1195415. DOI: 10.1128/AAC.49.9.3903-3909.2005. View

van Ogtrop M, Andes D, Stamstad T, Conklin B, Weiss W, Craig W . In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2000; 44(4):943-9. PMC: 89796. DOI: 10.1128/AAC.44.4.943-949.2000. View

Zhanel G, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J . The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004; 64(1):63-88. DOI: 10.2165/00003495-200464010-00005. View

Lucet J, Herrmann M, Rohner P, Auckenthaler R, Waldvogel F, Lew D . Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1990; 34(12):2312-7. PMC: 172053. DOI: 10.1128/AAC.34.12.2312. View

10.

Noskin G . Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005; 41 Suppl 5:S303-14. DOI: 10.1086/431672. View

11.

Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G . Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007; 51(5):1656-60. PMC: 1855569. DOI: 10.1128/AAC.00350-06. View

12.

Hiramatsu K . Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2002; 1(3):147-55. DOI: 10.1016/S1473-3099(01)00091-3. View

13.

Schaad H, Chuard C, Vaudaux P, Waldvogel F, Lew D . Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1994; 38(8):1703-10. PMC: 284625. DOI: 10.1128/AAC.38.8.1703. View

14.

Chang S, Sievert D, Hageman J, Boulton M, Tenover F, Downes F . Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003; 348(14):1342-7. DOI: 10.1056/NEJMoa025025. View

15.

Draghi D, Tench S, Dowzicky M, Sahm D . Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy. 2008; 54(2):91-100. DOI: 10.1159/000118660. View

16.

Liu C, Chambers H . Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003; 47(10):3040-5. PMC: 201119. DOI: 10.1128/AAC.47.10.3040-3045.2003. View

17.

Schaad H, Bento M, Lew D, Vaudaux P . Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect Dis. 2006; 6:74. PMC: 1458349. DOI: 10.1186/1471-2334-6-74. View

18.

Petersen P, Bradford P . Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother. 2005; 49(9):3910-8. PMC: 1195416. DOI: 10.1128/AAC.49.9.3910-3918.2005. View

19.

Cagni A, Chuard C, Vaudaux P, Schrenzel J, Lew D . Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1995; 39(8):1655-60. PMC: 162802. DOI: 10.1128/AAC.39.8.1655. View

20.

Labthavikul P, Petersen P, Bradford P . In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother. 2003; 47(12):3967-9. PMC: 296180. DOI: 10.1128/AAC.47.12.3967-3969.2003. View